CoChat
Sign Up
Cited by 127Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatmentsNeurological Disease Mechanisms and Treatments

The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.

Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer’s pathology

Open access
Haure-Mirande, Jean-Vianney, Audrain, Mickael, Fanutza, Tomas, Kim, Soong Ho, Klein, William L., Glabe, Charles, Readhead, Ben, Dudley, Joel T., Blitzer, Robert D., Wang, Minghui, Zhang, Bin, Schadt, Eric E., Gandy, Sam, Ehrlich, Michelle E.·2017·Acta Neuropathologica
DOI 10.1007/s00401-017-1737-3PMC PMC5645450
Open this paper in CoChat — free accountOpen PDF

Abstract

Conventional genetic approaches and computational strategies have converged on immune-inflammatory pathways as key events in the pathogenesis of late onset sporadic Alzheimer’s disease (LOAD). Mutations and/or differential expression of microglial specific receptors such as TREM2, CD33, and CR3 have been associated with strong increased risk for developing Alzheimer’s disease (AD). DAP12 (DNAX-activating protein 12)/TYROBP, a molecule localized to microglia, is a direct partner/adapter for TREM2, CD33, and CR3. We and others have previously shown that TYROBP expression is increased in AD patients and in mouse models. Moreover, missense mutations in the coding region of TYROBP have recently been identified in some AD patients. These lines of evidence, along with computational analysis of LOAD brain gene expression, point to DAP12/TYROBP as a potential hub or driver protein in the pathogenesis of AD. Using a comprehensive panel of biochemical, physiological, behavioral, and transcriptomic assays, we evaluated in a mouse model the role of TYROBP in early stage AD. We crossed an Alzheimer’s model mutant APP KM670/671NL /PSEN1 Δexon9 (APP/PSEN1) mouse model with Tyrobp −/− mice to generate AD model mice deficient or null for TYROBP (APP/PSEN1; Tyrobp +/− or APP/PSEN1; Tyrobp −/−). While we observed relatively minor effects of TYROBP deficiency on steady-state levels of amyloid-β peptides, there was an effect of Tyrobp deficiency on the morphology of amyloid deposits resembling that reported by others for Trem2 −/− mice. We identified modulatory effects of TYROBP deficiency on the level of phosphorylation of TAU that was accompanied by a reduction in the severity of neuritic dystrophy. TYROBP deficiency also altered the expression of several AD related genes, including Cd33. Electrophysiological abnormalities and learning behavior deficits associated with APP/PSEN1 transgenes were greatly attenuated on a Tyrobp-null background. Some modulatory effects of TYROBP on Alzheimer’s-related genes were only apparent on a background of mice with cerebral amyloidosis due to overexpression of mutant APP/PSEN1. These results suggest that reduction of TYROBP gene expression and/or protein levels could represent an immune-inflammatory therapeutic opportunity for modulating early stage LOAD, potentially leading to slowing or arresting the progression to full-blown clinical and pathological LOAD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00401-017-1737-3

Cites

88 of 88 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 A decrease in TYROBP protein impairs Aβ deposits compaction, microglial activation, and recruitment around Aβ deposits in 4-month-old APP/PSEN1 mice. a Images of Iba1-immunostained microglia (green) and 6E10-immunoreactive plaques (red) in frontal cortices and hippocampi of APP/PSEN1, APP/PSEN1; Tyrobp +/− and APP/PSEN1; Tyrobp −/− mice. Arrows indicate location of the plaques. Scale bar 500 µm. b Quantification of the number of 6E10-immunoreactive Aβ deposits in cortices and hippocampi (Hip) of APP/PSEN1, APP/PSEN1; Tyrobp +/− and APP/PSEN1; Tyrobp −/− mice. c Measurements of the size of 6E10-immunoreactive Aβ deposits in cortices of APP/PSEN1 mice WT, deficient or null for Tyrobp. d Quantification of the number of Iba1-immunostained microglia in frontal cortices and hippocampi of APP/PSEN1, APP/PSEN1; Tyrobp +/− and APP/PSEN1; Tyrobp −/− mice. e, f Images of Iba1-immunostained microglia (green) and 6E10-immunoreactive plaques (red) and quantification of numbers of cortices plaque-associated microglia located on or within 30 µm radius of 6E10 immunoreactive Aβ plaques in APP/PSEN1, APP/PSEN1; Tyrobp +/− and APP/PSEN1; Tyrobp −/− mice. n = 3–4 mice per group. Scale bar 10 µm. g–i Images of thioflavin S-labeled amyloid plaques (g), circularity (h) and quantification of fluorescence intensity (i) of thioflavin S-labeled amyloid plaques from APP/PSEN1, APP/PSEN1; Tyrobp +/− and APP/PSEN1; Tyrobp −/− mice. n = 3–4 mice per group. Scale bar 5 µm. j, k Images of phagocytic microglial marker CD68 (green) and Iba1 (red) co-immunostaining (j) and quantification of fluorescence intensity of CD68 (k) in APP/PSEN1, APP/PSEN1; Tyrobp +/− and APP/PSEN1; Tyrobp −/− mice. n = 3–4 mice per group. Scale bar 30 µm. i Western blot analysis of CD68 in brain protein homogenates from APP/PSEN1, APP/PSEN1; Tyrobp +/− and APP/PSEN1; Tyrobp −/− mice. n = 3–6 mice per group. At least two independent western blot analyses were performed. Representative immunoreactive bands from the same western blot are shown on the right. One-way ANOVA corrected for multiple comparisons (Tukey) was used for (c, h, i, k) and Two-way ANOVA corrected for multiple comparisons (Tukey) was used for (b, d, f, l), *p < 0.05; ***p < 0.001; ****p < 0.0001. Data presented as mean ± SEM
Fig. 1 A decrease in TYROBP protein impairs Aβ deposits compaction, microglial activation, and recruitment around Aβ deposits in 4-month-old APP/PSEN1 mice. a Images of Iba1-immunostained microglia (green) and 6E10-immunoreactive plaques (red) in frontal cortices and hippocampi of APP/PSEN1, APP/PSEN1; Tyrobp +/− and APP/PSEN1; Tyrobp −/− mice. Arrows indicate location of the plaques. Scale bar 500 µm. b Quantification of the number of 6E10-immunoreactive Aβ deposits in cortices and hippocampi (Hip) of APP/PSEN1, APP/PSEN1; Tyrobp +/− and APP/PSEN1; Tyrobp −/− mice. c Measurements of the size of 6E10-immunoreactive Aβ deposits in cortices of APP/PSEN1 mice WT, deficient or null for Tyrobp. d Quantification of the number of Iba1-immunostained microglia in frontal cortices and hippocampi of APP/PSEN1, APP/PSEN1; Tyrobp +/− and APP/PSEN1; Tyrobp −/− mice. e, f Images of Iba1-immunostained microglia (green) and 6E10-immunoreactive plaques (red) and quantification of numbers of cortices plaque-associated microglia located on or within 30 µm radius of 6E10 immunoreactive Aβ plaques in APP/PSEN1, APP/PSEN1; Tyrobp +/− and APP/PSEN1; Tyrobp −/− mice. n = 3–4 mice per group. Scale bar 10 µm. g–i Images of thioflavin S-labeled amyloid plaques (g), circularity (h) and quantification of fluorescence intensity (i) of thioflavin S-labeled amyloid plaques from APP/PSEN1, APP/PSEN1; Tyrobp +/− and APP/PSEN1; Tyrobp −/− mice. n = 3–4 mice per group. Scale bar 5 µm. j, k Images of phagocytic microglial marker CD68 (green) and Iba1 (red) co-immunostaining (j) and quantification of fluorescence intensity of CD68 (k) in APP/PSEN1, APP/PSEN1; Tyrobp +/− and APP/PSEN1; Tyrobp −/− mice. n = 3–4 mice per group. Scale bar 30 µm. i Western blot analysis of CD68 in brain protein homogenates from APP/PSEN1, APP/PSEN1; Tyrobp +/− and APP/PSEN1; Tyrobp −/− mice. n = 3–6 mice per group. At least two independent western blot analyses were performed. Representative immunoreactive bands from the same western blot are shown on the right. One-way ANOVA corrected for multiple comparisons (Tukey) was used for (c, h, i, k) and Two-way ANOVA corrected for multiple comparisons (Tukey) was used for (b, d, f, l), *p < 0.05; ***p < 0.001; ****p < 0.0001. Data presented as mean ± SEMCC BY · PubMed Central
Fig. 2 A decrease in TYROBP protein decreases oligomeric Aβ levels and alters phospho-TAU, synaptophysin, LAMP1, and complement C3 levels in 4-month-old APP/PSEN1 mice. a–c Hemibrains of male and female APP/PSEN1 (n = 4–6), APP/PSEN1; Tyrobp +/− (n = 3–8) and APP/PSEN1; Tyrobp −/− (n = 3–4) mice were processed via differential detergent solubilization to produce fractions of TBS soluble, Triton-X soluble, and formic acid soluble Aβ. Oligomeric Aβ was assessed from the TBS-soluble fraction via dot blot analyses using NU-4 (a), A11 (b) and OC (c) antibodies. d–i Western blot analysis in brain protein homogenates from 4-month-old male and female mice WT, Tyrobp +/−, Tyrobp −/− and APP/PSEN1, APP/PSEN1; Tyrobp +/− and APP/PSEN1; Tyrobp −/− mice. d, e Phospho-tau (AT8 epitope)/total tau ratio for d WT, Tyrobp +/−, Tyrobp −/− mice and e APP/PSEN1, APP/PSEN1; Tyrobp +/− and APP/PSEN1; Tyrobp −/− mice. f, g Synaptophysin level for f WT, Tyrobp +/−, Tyrobp −/− mice and g APP/PSEN1, APP/PSEN1; Tyrobp +/− and APP/PSEN1; Tyrobp −/− mice. h Marker of dystrophic neurites (Lamp1) in APP/PSEN1, APP/PSEN1; Tyrobp +/− and APP/PSEN1; Tyrobp −/− mice. i Complement C3 in APP/PSEN1, APP/PSEN1; Tyrobp +/− and APP/PSEN1; Tyrobp −/− mice. At least two independent western blot analyses were performed. Representative immunoreactive bands from the same western blot are shown on the right. n = 3–6 mice per group. Two-way ANOVA corrected for multiple comparisons (Tukey) was used for all statistical comparisons in male and female mice, *p < 0.05; **p < 0.01; ***p < 0.001, ****p < 0.0001. Data presented as mean ± SEM
Fig. 2 A decrease in TYROBP protein decreases oligomeric Aβ levels and alters phospho-TAU, synaptophysin, LAMP1, and complement C3 levels in 4-month-old APP/PSEN1 mice. a–c Hemibrains of male and female APP/PSEN1 (n = 4–6), APP/PSEN1; Tyrobp +/− (n = 3–8) and APP/PSEN1; Tyrobp −/− (n = 3–4) mice were processed via differential detergent solubilization to produce fractions of TBS soluble, Triton-X soluble, and formic acid soluble Aβ. Oligomeric Aβ was assessed from the TBS-soluble fraction via dot blot analyses using NU-4 (a), A11 (b) and OC (c) antibodies. d–i Western blot analysis in brain protein homogenates from 4-month-old male and female mice WT, Tyrobp +/−, Tyrobp −/− and APP/PSEN1, APP/PSEN1; Tyrobp +/− and APP/PSEN1; Tyrobp −/− mice. d, e Phospho-tau (AT8 epitope)/total tau ratio for d WT, Tyrobp +/−, Tyrobp −/− mice and e APP/PSEN1, APP/PSEN1; Tyrobp +/− and APP/PSEN1; Tyrobp −/− mice. f, g Synaptophysin level for f WT, Tyrobp +/−, Tyrobp −/− mice and g APP/PSEN1, APP/PSEN1; Tyrobp +/− and APP/PSEN1; Tyrobp −/− mice. h Marker of dystrophic neurites (Lamp1) in APP/PSEN1, APP/PSEN1; Tyrobp +/− and APP/PSEN1; Tyrobp −/− mice. i Complement C3 in APP/PSEN1, APP/PSEN1; Tyrobp +/− and APP/PSEN1; Tyrobp −/− mice. At least two independent western blot analyses were performed. Representative immunoreactive bands from the same western blot are shown on the right. n = 3–6 mice per group. Two-way ANOVA corrected for multiple comparisons (Tukey) was used for all statistical comparisons in male and female mice, *p < 0.05; **p < 0.01; ***p < 0.001, ****p < 0.0001. Data presented as mean ± SEMCC BY · PubMed Central
Fig. 3 A decrease in TYROBP protein alters excitatory synaptic transmission in the hippocampus in 4-month-old APP/PSEN1 mice and interacts with the APP/PSEN1 genotype. In all panels, summary graphs are shown on the left and representative traces on the right. a Basal synaptic function is increased in Tyrobp −/− mice, but is unaffected by other transgenic genotypes. The slope of the input/output relationship was steeper for the Tyrobp −/− mice than for all other genotypes (p < 0.05), which did not differ among themselves. b APP/PSEN1 mice showed reduced paired-pulse facilitation (PPF) relative to other genotypes, which did not differ among themselves. c Synaptically induced long-term depression (LTD) was impaired in all recombinant mice. Analysis over the final 5 min of the recordings showed the most profound deficits for Tyrobp −/− and APP/PSEN1;Tyrobp −/− mice, both of which were significantly less depressed than in APP/PSEN1 mice. Wild-type (WT) controls showed significantly greater depression than the other genotypes. One-way ANOVA corrected for multiple comparisons (Tukey) was used for statistical comparisons, *p < 0.05, **p < 0.01; ***p < 0.001. Data presented as mean as mean ± SEM
Fig. 3 A decrease in TYROBP protein alters excitatory synaptic transmission in the hippocampus in 4-month-old APP/PSEN1 mice and interacts with the APP/PSEN1 genotype. In all panels, summary graphs are shown on the left and representative traces on the right. a Basal synaptic function is increased in Tyrobp −/− mice, but is unaffected by other transgenic genotypes. The slope of the input/output relationship was steeper for the Tyrobp −/− mice than for all other genotypes (p < 0.05), which did not differ among themselves. b APP/PSEN1 mice showed reduced paired-pulse facilitation (PPF) relative to other genotypes, which did not differ among themselves. c Synaptically induced long-term depression (LTD) was impaired in all recombinant mice. Analysis over the final 5 min of the recordings showed the most profound deficits for Tyrobp −/− and APP/PSEN1;Tyrobp −/− mice, both of which were significantly less depressed than in APP/PSEN1 mice. Wild-type (WT) controls showed significantly greater depression than the other genotypes. One-way ANOVA corrected for multiple comparisons (Tukey) was used for statistical comparisons, *p < 0.05, **p < 0.01; ***p < 0.001. Data presented as mean as mean ± SEMCC BY · PubMed Central
Fig. 4 A decrease in TYROBP protein improves spatial learning and memory in the Barnes Maze Test in 4-month-old APP/PSEN1 mice. a–d 6 groups of 4-month-old mice were used: wild-type (WT) (n = 14), Tyrobp +/− (n = 9), Tyrobp −/− (n = 10), APP/PSEN1 (n = 5), APP/PSEN1; Tyrobp +/− (n = 9) or APP/PSEN1; Tyrobp −/− (n = 11). a, b Mean latencies to enter the target hole for a APP/PSEN1 negative mice and b APP/PSEN1 positive mice. c, d Mean distances traveled for c APP/PSEN1 negative mice and d APP/PSEN1 positive mice. Two-way ANOVA corrected for multiple comparisons (Tukey) was used for all statistical comparisons, *p < 0.05; **p < 0.01; ***p < 0.001. Data presented as mean ± SEM
Fig. 4 A decrease in TYROBP protein improves spatial learning and memory in the Barnes Maze Test in 4-month-old APP/PSEN1 mice. a–d 6 groups of 4-month-old mice were used: wild-type (WT) (n = 14), Tyrobp +/− (n = 9), Tyrobp −/− (n = 10), APP/PSEN1 (n = 5), APP/PSEN1; Tyrobp +/− (n = 9) or APP/PSEN1; Tyrobp −/− (n = 11). a, b Mean latencies to enter the target hole for a APP/PSEN1 negative mice and b APP/PSEN1 positive mice. c, d Mean distances traveled for c APP/PSEN1 negative mice and d APP/PSEN1 positive mice. Two-way ANOVA corrected for multiple comparisons (Tukey) was used for all statistical comparisons, *p < 0.05; **p < 0.01; ***p < 0.001. Data presented as mean ± SEMCC BY · PubMed Central
Fig. 5 Differential gene expression analysis suggests potential molecular mechanisms associated with TYROBP deficiency. a–c Differential gene expression analysis in dentate gyrus and prefrontal cortex of Tyrobp −/− , Tyrobp +/− and WT mice. a Number of up- and down-regulated genes in Tyrobp −/− and Tyrobp +/− vs. WT and Tyrobp −/− vs. Tyrobp +/−. b Top 10 differentially expressed genes in b dentate gyrus of Tyrobp −/− vs. WT and c prefrontal cortex of Tyrobp −/− vs. WT. Bolding highlights differentially expressed genes shared across dentate gyrus and prefontal cortex. RNA sequencing was performed on a total of 47 samples (Tyrobp −/− n = 8 males and 8 females, Tyrobp +/− n = 8 males and 8 females, and WT n = 7–8 samples, eight males and eight females, for each brain regions). All analyses were corrected for sex effect. Differential gene expression threshold was set at fold change ≥1.2 and adjusted p value <0.1. DG dentate gyrus, PC prefrontal cortex. d–g Differential gene expression analysis in prefrontal cortex of APP/PSEN1;Tyrobp −/− , APP/PSEN1; Tyrobp +/− and APP/PSEN1 mice at 4-months-old. d Number of up- and down-regulated genes in APP/PSEN1;Tyrobp −/− and APP/PSEN1;Tyrobp +/− vs. APP/PSEN1 and APP/PSEN1; Tyrobp −/− vs. APP/PSEN1; Tyrobp +/−. e Top 10 differentially expressed genes in APP/PSEN1; Tyrobp +/−vs. APP/PSEN1; f APP/PSEN1; Tyrobp −/− vs. APP/PSEN1 and g APP/PSEN1; Tyrobp −/− vs. APP/PSEN1; Tyrobp +/−. RNA sequencing was performed on a total of 23 samples comprising of both male and female mice (n = 7–8 samples per genotype). All analyses were corrected for sex effect. Differential gene expression threshold was set at fold change ≥1.2 and false discovery rate (FDR) <0.1. (See Suppl. 3 and 4 for full list of differentially expressed genes)
Fig. 5 Differential gene expression analysis suggests potential molecular mechanisms associated with TYROBP deficiency. a–c Differential gene expression analysis in dentate gyrus and prefrontal cortex of Tyrobp −/− , Tyrobp +/− and WT mice. a Number of up- and down-regulated genes in Tyrobp −/− and Tyrobp +/− vs. WT and Tyrobp −/− vs. Tyrobp +/−. b Top 10 differentially expressed genes in b dentate gyrus of Tyrobp −/− vs. WT and c prefrontal cortex of Tyrobp −/− vs. WT. Bolding highlights differentially expressed genes shared across dentate gyrus and prefontal cortex. RNA sequencing was performed on a total of 47 samples (Tyrobp −/− n = 8 males and 8 females, Tyrobp +/− n = 8 males and 8 females, and WT n = 7–8 samples, eight males and eight females, for each brain regions). All analyses were corrected for sex effect. Differential gene expression threshold was set at fold change ≥1.2 and adjusted p value <0.1. DG dentate gyrus, PC prefrontal cortex. d–g Differential gene expression analysis in prefrontal cortex of APP/PSEN1;Tyrobp −/− , APP/PSEN1; Tyrobp +/− and APP/PSEN1 mice at 4-months-old. d Number of up- and down-regulated genes in APP/PSEN1;Tyrobp −/− and APP/PSEN1;Tyrobp +/− vs. APP/PSEN1 and APP/PSEN1; Tyrobp −/− vs. APP/PSEN1; Tyrobp +/−. e Top 10 differentially expressed genes in APP/PSEN1; Tyrobp +/−vs. APP/PSEN1; f APP/PSEN1; Tyrobp −/− vs. APP/PSEN1 and g APP/PSEN1; Tyrobp −/− vs. APP/PSEN1; Tyrobp +/−. RNA sequencing was performed on a total of 23 samples comprising of both male and female mice (n = 7–8 samples per genotype). All analyses were corrected for sex effect. Differential gene expression threshold was set at fold change ≥1.2 and false discovery rate (FDR) <0.1. (See Suppl. 3 and 4 for full list of differentially expressed genes)CC BY · PubMed Central
Fig. 6 Gene enrichment analysis summary for prefrontal cortex of 4-month-old APP/PSEN1;Tyrobp −/− , APP/PSEN1; Tyrobp +/− and APP/PSEN1 mice at suggests potential molecular mechanisms associated with TYROBP deficiency. a Schematic overview of comparisons between mouse groups. b Enrichment analysis and selected GO terms (DAVID) and diseases and functions (Ingenuity Pathway Analysis) in APP/PSEN1; Tyrobp −/− vs. APP/PSEN1, c in APP/PSEN1; Tyrobp +/− vs. APP/PSEN1, d in APP/PSEN1; Tyrobp −/− vs. in APP/PSEN1; Tyrobp +/−. Enrichments shown were selected for known or suspected relevance to AD pathophysiology. Gene set enrichment threshold was set at p value <0.05. (See Suppl. 5 for full list of enrichments)
Fig. 6 Gene enrichment analysis summary for prefrontal cortex of 4-month-old APP/PSEN1;Tyrobp −/− , APP/PSEN1; Tyrobp +/− and APP/PSEN1 mice at suggests potential molecular mechanisms associated with TYROBP deficiency. a Schematic overview of comparisons between mouse groups. b Enrichment analysis and selected GO terms (DAVID) and diseases and functions (Ingenuity Pathway Analysis) in APP/PSEN1; Tyrobp −/− vs. APP/PSEN1, c in APP/PSEN1; Tyrobp +/− vs. APP/PSEN1, d in APP/PSEN1; Tyrobp −/− vs. in APP/PSEN1; Tyrobp +/−. Enrichments shown were selected for known or suspected relevance to AD pathophysiology. Gene set enrichment threshold was set at p value <0.05. (See Suppl. 5 for full list of enrichments)CC BY · PubMed Central
Fig. 7 Computational analysis of a current pharmacopeia database identified compounds that would be predicted to cause up- or down-regulation of TYROBP expression. a Compounds were scored and ranked according to their associated TYROBP expression fold change, and then used as the basis for a secondary enrichment analysis to identify drug targets that associate with up- or down-regulation of TYROBP. Top 10 compounds that b up-regulate and c down-regulate TYROBP are shown. Drug targets enriched among compounds that d up-regulate, and e down-regulate TYROBP are shown
Fig. 7 Computational analysis of a current pharmacopeia database identified compounds that would be predicted to cause up- or down-regulation of TYROBP expression. a Compounds were scored and ranked according to their associated TYROBP expression fold change, and then used as the basis for a secondary enrichment analysis to identify drug targets that associate with up- or down-regulation of TYROBP. Top 10 compounds that b up-regulate and c down-regulate TYROBP are shown. Drug targets enriched among compounds that d up-regulate, and e down-regulate TYROBP are shownCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 127

Related

See all

Metadata

Authors
Haure-Mirande, J.-V., Audrain, M., Fanutza, T., Kim, S. H., Klein, W. L., Glabe, C., Readhead, B., Dudley, J. T., Blitzer, R. D., Wang, M., Zhang, B., Schadt, E. E., Gandy, S., & Ehrlich, M. E.
Affiliations
  • Icahn School of Medicine at Mount Sinai (US)
  • Northwestern University (US)
  • University of California, Irvine (US)
Corresponding author
  • Gandy, Sam
  • Ehrlich, Michelle E.
ORCID
Venue
Acta Neuropathologica
Publisher
Springer Science and Business Media LLC
Published
2017-06-13
Volume
134
Issue
5
Pages
769-788
ISSN
  • 0001-6322 (ISSN-L)
  • 1432-0533
DOI
10.1007/s00401-017-1737-3
PMC
PMC5645450
OpenAlex
W2625865615
Cited by
127
References
88
Citations by year
2026: 7 · 2025: 10 · 2024: 22 · 2023: 11 · 2022: 12 · 2021: 15 · 2020: 22 · 2019: 11 · 2018: 14 · 2017: 3
FWCI
6.81
Type
journal article
Language
en
Open access
Licence
Locations
  • Acta Neuropathologica (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders
  • National Institute on Aging (AG046170)
  • Louis B. Mayer foundation
  • Cure Alzheimer's Fund
  • BrightFocus Foundation (A2016482F)
  • Sarah and Gideon Gartner Foundation
  • Georgianne and Dr Reza Khatib Foundation
  • Werber Family Foundation
  • Jennifer and Scott Moskowitz Foundation
  • Jane Martin and Stuart Katz Foundation
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
Keywords
TYROBP, DAP12, TREM2, CD33, CR3, Alzheimer's disease, microglia, neuroinflammation, amyloid-beta, tau phosphorylation, neuritic dystrophy, learning deficits, neuroprotection, gene knockout, early Alzheimer's disease, cerebral amyloidosis
MeSH terms
Alzheimer Disease, Animals, Brain, Disease Models, Animal, Mutation, Phosphorylation, tau Proteins, Microglia, Mice, Knockout, Maze Learning, Adaptor Proteins, Signal Transducing, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review